

Research Article

In Vitro Release of 5-Fluorouracil and Methotrexate from Different Thermosensitive Chitosan Hydrogel Systems

Ahmed M. Mohammed,1,3 Shaaban K. Osman,1 Khaled I. Saleh,1 and Ahmed M. Samy2

Received 12 July 2019; accepted 30 March 2020; published online 13 May 2020

Abstract. 5-Fluorouracil is a member of cytotoxic drugs with poor selectivity to cancer cells. Currently, systemic administration of this anti-cancer drug (oral or injection) exposes normal tissues to the drug-induced toxicity. Nowadays, attention has been greatly directed towards in situ gel-forming systems that can be injected into the affected tissues in its sol form with a minimally invasive technique. More specifically, chitosan hydrogel systems were in focus due to their antibacterial effect as well as their biodegradable, biocompatible, and mucoadhesive properties. In the present work, 5-fluorouracil was loaded on various thermosensitive chitosan hydrogel systems cross linked with different linking agents like β-glycerophosphate, pluronic F127, and hydroxyapatite. Also, methotrexate was added to 5-fluorouracil in order to gain its previously reported synergistic effects. Firstly, a compatibility study was performed using UV-spectrophotometric, infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) techniques to exclude the possibility of any physical or chemical interactions between the selected drugs and excipients. The prepared hydrogel systems were characterized for their physicochemical properties including organoleptic, pH, syringeability and injectability, viscosity, and gelation temperature ($T_{gel}$) by various analysis techniques. Moreover, the in vitro release behavior of 5-fluorouracil and methotrexate was determined with a modified analytical method. The results indicated that chitosan hydrogel system cross-linked with a combination of β-glycerophosphate, and 10 % pluronic F127 (F4) showed the most suitable physicochemical properties and release profile. Accordingly, this formula can be considered as a missionary system for localized sustained delivery of cytotoxic drugs.

KEY WORDS: thermosensitive; chitosan; In vitro; 5-fluorouracil; methotrexate and hydrogel.

INTRODUCTION

Current systemic administration of anti-cancer drugs exposes normal tissues to the drug-induced toxicity. This is because most cytotoxic drugs are non-selective and cannot distinguish between cancer and normal cells [1]. In addition, rapid release of the loaded dose causes rapid elevation of the drug level with unintended side effects at the peak followed by shape declining and insufficient therapeutic effect at the low drug level [2]. 5-fluorouracil (5-FU) is an anti-cancer drug having structural similarity to pyrimidine bases (Fig. 1), interfering with thymidylate synthase enzyme action and preventing DNA replication [3]. It was reported that pretreatment with methotrexate (MTX) increases 5-FU uptake by cells, due to inhibition of purine synthesis by MTX as a result of increased levels of intracellular phosphoribosyl-pyrophosphate. Inhibition of purine synthesis will result in accumulation of N5,N10-methylene tetrahydrofolate which is an essential factor for tight binding of 5-fluorouracil active metabolite to thymidylate synthetase enzyme (TS) [4, 5].

To overcome the problem of poor selectivity, systemic administration of these anti-cancer drugs has been replaced by localized targeting and controlled drug delivery systems and it shows promising results in the fields of chemotherapy [6].

Different sustained-release injectable systems were basically designed like implants [7, 8], nano and microparticles [7, 9], and liposomes [10] to provide localized drug delivery. However, these systems show limited loading capacity and require further surgical operations to insert it at the tumor site which results in extra risks and costs of these systems [11]. These problems have directed the researchers towards injectable biopolymer-based hydrogels for localized drug delivery.

1 Department of Pharmaceutics and Industrial pharmacy, College of Pharmacy, Al-Azhar University, Assiut, Egypt.
2 Department of Pharmaceutics and Industrial pharmacy, College of Pharmacy, Al-Azhar University, Cairo, Egypt.
3 To whom correspondence should be addressed. (e-mail: ahmedabdelaal@azhar.edu.eg)
Chitosan (CH), a natural biopolymer with similar structure and bioactivity to glycosaminoglycan, has been used as injectable hydrogel due to its antibacterial, mucoadhesive, biocompatible, and biodegradable properties [12]. Different chemically inert cross-linking agents like β-glycerophosphate, Pluronic F127, and hydroxyapatite (Ca₅ (PO₄)₃ OH) were used in preparation of chitosan hydrogel in order to improve its physicochemical properties of chitosan hydrogel [13–15].

The present work was aiming to formulate a novel 5-FU with MTX systems in different biodegradable chitosan hydrogels for localized injection at the cancer tissue using different cross-linking agents like β-glycerophosphate (β-GP), pluronic F127 (Pl F127), and hydroxyapatite (HA). The compatibility study was achieved by using UV-spectrophotometric, infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC) techniques for detection of any drug-excipient interactions. The formulated hydrogels were characterized by different analytical techniques for their physicochemical properties including drug content, pH, syringeability and injectability, viscosity, and gelation temperature (Tgel).

Moreover, an analytical procedure was developed for quantitative determination of 5-FU in the presence of MTX in the release medium. The most suitable formulae will be selected for further studies.

MATERIALS AND METHODS

Materials

5-fluorouracil (5-FU) was purchased from Applichem for pharmaceuticals Co., Gmbh (Germany). Medium-molecular-weight Chitosan of 190 KDa, pluronic F127, and β-glycerophosphate (β-GP) were purchased from Fluka BioChemika (Switzerland). Methotrexate (MTX) was obtained in lyophilized form from Haupt Pharma GmbH-Chemajet Co., (Germany). Acetic acid, calcium chloride, and potassium dihydrogen phosphate were obtained from Al-Nasr Pharm. Chem. Co., (Cairo, Egypt). All other solvents and materials were of high analytical grade.

Compatibility Studies

Compatibility studies for drugs and excipients were performed to exclude the possibility of chemical interactions which may affect the therapeutic activity of the drugs [16]. Compatibility study was carried out by using UV-spectrophotometric, infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC).

Scanning Ultraviolet Absorption Study

A 1% solution of each excipient in distilled water was scanned in the presence and absence of the drugs using distilled water as a blank. This study was done to indicate the presence of any interference caused by the investigated excipients on the maximum absorbance of the drug in the used dilution range [17]. The maximum absorbance was measured spectrophotometrically using UV-visible spectrophotometer (UV-1601, Shimadzu, Japan).

FTIR Spectroscopy

The IR absorption spectra of pure components and physical mixture (1:1 ratio) were measured using IR-spectrophotometer (IR-476, Shimadzu, Japan) at a range of 4000–400 cm⁻¹ [18]. The samples were compressed into KBr discs by the aid of IR compression machine [19].

Differential Scanning Calorimetry

DSC study was performed using DSC-Thermal analyzer (DSC-T50, Shimadzu, Japan). Samples were carefully weighed into aluminum pans and sealed. The temperature range for the thermogram was 30 to 350°C, and the samples were heated at rate of 10°C/min [20].

Fig. 1. Chemical structure of 5-fluorouracil (a), methotrexate (b) and chitosan (c)
UV-Spectrophotometric Analysis of 5-FU in the Presence of MTX

There are some instances in which the presence of one species in a sample does not interfere with the measurement of another one in the same sample [21]. In the present work, the absorption of light by the components of the sample solution is additive. Then, by choosing wavelengths where the absorption of the first drug is strong and the second one is weak, it is still possible to determine their concentrations [21]. Firstly, the absorption spectrum of the two drugs individually was determined and chooses wavelengths which differentiate their response ($\lambda_{\text{max}}$). Then, Beer’s Law curve over range of concentrations for each drug was constructed. The various absorptivity constants ($k$) are determined from Beer’s Law plots for the separate components at the two wavelengths which are chosen for the analysis. With a two-unknown-component mixture, two mathematical equations were generated and solved simultaneously to obtain the concentrations of the two unknown components [17].

Preparation of Thermosensitive Chitosan Hydrogel Systems

Chitosan solution was prepared according to Chenite et al.’s method [22]. Briefly, medium molecular weight chitosan of 190 KDa (1.8% w/w) was dissolved in 0.1 M acetic acid. The chitosan powder was sprinkled over the solvent under stirring for 30 min for complete mixing. Afterward, cold aqueous solutions of different cross-linking agents including $\beta$-GP (35% w/w), pluronic F127 (20% w/w), or hydroxyapatite (2.63% w/w) were prepared and chilled drop wise along with the previously prepared chitosan solutions (1:1 ratio) in an ice bath for 15 min, as presented in Table I. Finally, the obtained chitosan thermosensitive hydrogels (F1, F2, F3, and F4) were stored at 8°C [14, 15].

Drug Loading

The method of drug loading greatly affects the release rate and bioavailability of the drugs. In the present work, both 5-FU and MTX were added to chitosan solution at concentration of 0.1 and 0.05% w/w, respectively, with agitating until it was dissolved thoroughly [23].

Characterization of Chitosan Hydrogels

Drug Content

One-gram sample containing amount equivalent to 1 mg and 0.5 mg of 5-FU and MTX, respectively, was taken and dissolved in a sufficient quantity of distilled water. The obtained solution was filtered by using Whatman filter paper. The filtrate was appropriately diluted with distilled water, and the drug content was determined spectrophotometrically at two $\lambda_{\text{max}}$ (260 and 302) using UV-Visible spectrophotometer [23].

Visual Inspection (Organoleptic Properties)

The prepared systems were visually examined in sol and gel forms for their purity, homogeneity, fluidity, and phase separation [24].

pH Determination

The pH of the prepared hydrogel systems was simply measured by immersing the probe of the pH meter into the samples using Ama Digital pH meter (Ama Co., Germany) [25].

Table I. Percent Composition (w/w) of Chitosan Hydrogel Formulations Containing Different Cross-Linking Agents

| Formulation code | Chitosan solution | Cross-linking agent solutions | $\beta$-Glycerophosphate | Pluronic F127 | Hydroxyapatite |
|------------------|-------------------|-------------------------------|-------------------------|--------------|---------------|
| F1               | 1.8               | 35                            | –                       | –            | –             |
| F2               | 1.8               | –                             | 20                      | –            | –             |
| F3               | 1.8               | –                             | –                       | 2.63         | –             |
| F4               | 1.8               | 35                            | –                       | 10           | –             |

Table II. Kinetic Model Equations

| Kinetic models        | Equations                  |
|-----------------------|----------------------------|
| Zero order            | $Q_t = Q_0 - K_0t$         |
| First order           | $\log Q_t = \log Q_0 - \frac{K_0}{\lambda_{\text{max}}}t$ |
| Korsmeyer-Peppas      | $\log Q_t = \log K + n\log t$ |
| Higuchi’s equation    | $Q_t = K_0 \sqrt{t}$     |

($Q_t$ is the quantity of the drug released at time $t$, $K$ is the release rate constant, and $n$ is the diffusional exponent that characterizes the best fitted release mechanism)
Viscosity Measurement

At room temperature (25 ± 1°C), the viscosity of the prepared chitosan hydrogel solutions was measured using an Ostwald U tube capillary viscometer. Briefly, liquid is introduced into the viscometer until the level reaches the mark. The viscometer is fixed vertically in a thermostatic bath and allowed to attain the required temperature. The sample volume is adjusted and the liquid is sucked or blown into the other arm until the liquid is just above the mark. The suction or pressure is released, and the time taken for the bottom of the liquid to fall from the top mark to the bottom mark is noted [26].

At 37°C, the viscosity of chitosan hydrogels was measured with Brookfield DV-III ultra viscometer using T-bar spindle (T-D 94) at 50 rpm [27].

Syringeability and Injectability

Syringeability and injectability are of particular significance for any parenteral dosage forms. Suitable consistency is necessary in order to extrude the gel solution from the needle into the body in a proper manner. Practically, syringeability test was simply performed by filling syringe-needle system with the liquid preparations and injecting the solution into a piece of meat by the aid of finger pressure at room temperature [28].

Sol-Gel Transition Temperature Measurement

The cold solutions of different hydrogel systems were heated on water bath in range 8 to 40°C at constant rate with continuous stirring. The temperature at which the magnetic bar stopped to move due to gelation was recorded as the gelation temperature (T_gel) [29].

In Vitro Drug Release

Samples of 0.5 ml (500 mcg 5-FU and 250 mcg MTX) were placed in Eppendorf tubes and incubated at 37°C for 1 h for gelation. The formed gels were incubated with 1 ml of phosphate buffer solution (pH 7.4) at 37°C while shaking at 50 rpm. At certain time intervals (0.5, 1, 2, 4, ..... 34 days), 0.5 ml samples were taken and replaced by equal volume of fresh buffer solutions to maintain the sink conditions [30]. The amount of the drug released was estimated by the newly evaluated method for simultaneous analysis of 5-FU and MTX mixture by UV-spectrophotometric method. All measurements were performed in triplicate and the data were reported as means ± SD.

Kinetic Treatment of 5-FU and MTX Release Data

The in vitro release data were analyzed according various kinetic models including zero order, first order [31], Korsmeyer-Peppas [32], and Higuchi diffusion [33], in order to determine the most appropriate release model that describes the drug release pattern. Model selection was based on the correlation coefficient (r) values for the involved parameters as suggested by Burnham and Anderson (Table II) [34].
RESULTS AND DISCUSSION

Compatibility Studies

Scanning Ultraviolet Absorption Study

The ultraviolet scanning of 1% solution was done using double-beam spectrophotometer, UV-1601 (Shimadzu Co., Japan). It was found that the components used in this study showed no absorbance at the specified selected wave lengths (λ\text{max}) of 5-FU (266) and MTX (302). On the other hand, the scanning of the 5-FU in the presence of MTX showed certain degree of cross overlapping at the selected absorbance values, which represents a great problem in measuring of 5-FU in the presence of MTX.

FTIR Spectroscopy

The IR spectra of 5-FU, MTX, chitosan, Pl f127, and physical mixture were recorded using infrared spectrophotometer (IR-476, Shimadzu Co., Japan). Especially, the characteristic bands will be in focus in order to determine the possibility of interaction of 5-FU and MTX with chitosan hydrogel. The IR spectrum of the 5-FU (Fig. 2a) showed characteristic peaks at 1672 cm\(^{-1}\) corresponding to C=O stretching vibration, 1431 cm\(^{-1}\) due to C–H bending vibration, and 1247 cm\(^{-1}\) for C–N stretching vibration. The IR spectrum of MTX (Fig. 2b) showed two characteristic bands at 1603 cm\(^{-1}\) and 1624 cm\(^{-1}\) associated to carboxylate and amide C=O stretching vibration, respectively. Regarding IR spectrum of chitosan (Fig. 2c), it showed characteristic bands at 3420 cm\(^{-1}\) for O–H stretch, 2923 cm\(^{-1}\) for C–H stretch, 1651 cm\(^{-1}\) for C–O stretch of acetyl group, and 1574 cm\(^{-1}\) for N–H stretch. These data are in a good accordance with the previously reported data [35–37]. On the other hand, IR spectrum of the physical mixture (Fig. 2d) shows no significant difference in the positions of the absorption bands. The spectra can be simply regarded as combination of both of A, B, and C with the peak position of 5-FU in the physical mixture having little or no change and slightly diluted. These results indicate that 5-FU and MTX can be formulated in chitosan hydrogel without interaction with chitosan.

Differential Scanning Calorimetry

It has been considered that DSC is a well-developed fast technique for the analysis of drug-drug or drug-excipients interactions. The incompatibilities could be detected by the appearance, shifting, or disappearance of the characteristic endothermic or exothermic peaks and or variations in the corresponding values of enthalpy in the thermograms of drug-excipients mixtures [38].

As shown in Fig. 3a, 5-FU showed a sharp endothermic peak at 285°C corresponding to drug melting, in good agreement with the literature value [39]. DSC thermogram of MTX showed a broad endothermic peak at 122°C corresponds to the melting peak of MTX (Fig. 3b) [40]. DSC curves for purified chitosan (Fig. 3c), showed a broad endothermic peak around 70°C due to the loss of water. An exothermic peak was obtained at 296°C that can be ascribed to the decomposition of amine units [41]. With respect to thermogram of the physical mixture (Fig. 3d), only loss of the peaks intensity with no apparent changes in the characteristic bands of the pure components was observed. The observed short peak around 120°C may be attributed to dilution effect of the sample mixture. Also, forked appearance may be due to in intended contamination of the sample.

Table III. Physicochemical Properties of Different Chitosan Hydrogel Formulations

| Code | Drug content | pH   | Viscosity | Gelation point (°C) |
|------|--------------|------|-----------|---------------------|
|      | 5-FU MTX     |      | Sol (cP)  | Gel (cP)            |
| F1   | 100.5 ± 4.35 | 102.67 ± 5.22 | 6.5 ± 1.0 | 2.117 ± 0.06 | 114 ± 8 | 35.5 ± 0.5 |
| F2   | 103.0 ± 4.94 | 95.93 ± 2.41 | 6.36 ± 0.06 | 2.123 ± 0.03 | 117.8 ± 1.04 | 24.3 ± 1.1 |
| F3   | 102.17 ± 5.93 | 102.53 ± 2.0 | 7.3 ± 0.06 | 3.292 ± 0.07 | 153 ± 4.58 | 19.0 ± 1.0 |
| F4   | 102.0 ± 3.80 | 98.08 ± 5.16 | 6.7 ± 0.17 | 2.449 ± 0.04 | 120.8 ± 1.26 | 29.3 ± 1.5 |
UV-Spectrophotometric Analysis of 5-FU in the Presence of MTX

The results showed that $\lambda_{\text{max}}$ for 5-FU is around 266 nm, where absorbance is weak at 302 nm. On the other hand, MTX has maximum absorption ($\lambda_{\text{max}}$) at 302 nm but its absorption at 266 nm is still of significant value. From the Beer’s Law plots, the slopes ($k’s$ = absorptivity constants) for 5-FU and MTX at the relevant wavelengths were found to be 0.0533, 0.0232, 0.0012, and 0.0259 for $K_{1f}$, $K_{1m}$, $K_{2f}$, and $K_{2m}$, respectively. The concentration of each of the components in the unknown mixture can be calculated by setting up simultaneous equations and solving for the two unknowns as the following [21, 42]:

$$A_1 = k_{1f}C_f + k_{1m}C_m = 0.0533C_f + 0.0232C_m \quad (1)$$

$$A_2 = k_{2f}C_f + k_{2m}C_m = 0.0012C_f + 0.0259C_m \quad (2)$$

$$C_m = \frac{A_2 - 0.0225}{0.0254} \quad (3)$$

$$C_f = \frac{A_1 - 0.0232}{0.0533} \quad (4)$$

$A_1$ and $A_2$ are the absorbance of unknown mixture at the first wavelength (266) and the second wavelength (302),

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig5.png}
\caption{In vitro release profile of 5-FU an MTX from chitosan/$\beta$-GP hydrogel system (F1)}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig6.png}
\caption{In vitro release profile of 5-FU an MTX from chitosan/Pluronic F127 hydrogel system (F2)}
\end{figure}
respectively. \( C_f \) and \( C_m \) are the concentration of 5-FU and MTX, respectively.

### Preparation of Thermosensitive Chitosan Hydrogel Systems

All chitosan hydrogel systems were successfully prepared by mixing chitosan solutions with cross-linking agents in an ice path for 15 min (see Fig. 4). The calculated amounts of the drug were dissolved in the prepared solutions by stirring at 500 rpm for 30 min to ensure homogenous distribution of the drug.

### Characterization of the Prepared Chitosan Hydrogels

#### Drug Content Determination

All the prepared hydrogels were tested for their drug content. All investigated formulae was found to be within the range of 95–103% (see Table III). These results are considered to be sufficient for further studies.

#### Visual Inspection (Organolectic Properties)

The prepared chitosan hydrogels were visually examined for their organoleptic properties before and after gelation. The results showed that all the systems were clear and uniform with no lumps or phase separation in both sol and gel forms. The color was white and turbid in the gel form and clear colorless in the sol form. These results indicate the validity of the prepared hydrogels for parental administration.

#### pH Determination

It was observed that the pH of the prepared formulae F1, F2, and F4 was in the range of (6.2 to 6.9) and that of F3 was 7.3 (see Table III) indicating the utility of all formulations for
subcutaneous injection since. The higher pH value of F3 may be attributed to alkali imparting component (Na₂CO₃) of hydroxyapatite (Ca₅(PO₄)₃(OH) cross-linking agent. It was reported that pH of injectable hydrogels should lie in a pH range of 6.5–7.4 to avoid cell damage [43].

Viscosity Measurement

The viscosity of the prepared hydrogels in both sol and gel states was measured and is presented in Table III. The results showed that with the exception of F3 solution, all hydrogel solutions having certain degree of similarity in their rheological behaviors. This is because water is the major component in all formulations. However, in the case of F3 solution, higher viscosity may be attributed to higher viscosity of hydroxyapatite solution at low temperature as well as stronger interaction with chitosan solution after mixing [44]. Similarly for gel forms, the viscosity values were higher from F3 hydrogels compared to those of F1, F2, and F4 hydrogels. Noteworthy, sol-gel transition phenomenon is the major requirement for injectable hydrogel to provide certain degree of syringeability and injectability [45].

Syringeability and Injectability

The prepared chitosan solutions cross-linked with β-GP (F1), 20% Pl F127 (F2), or β-GP-10% Pl F127 (F4) were continuously extruding 0.5 cm within 5–10 s when 5 mm syringe was pressed with fingers with mild to moderate force. These results indicate smooth and easy injection of these solutions from the syringes to the meat sample. On the other hand, chitosan/HA solution (F3) shows high degree of

![Fig. 9. Kinetics release profiles of 5-FU from different chitosan hydrogels (F1, F2, F3, and F4) plotted according to zero-order mechanism](image)

![Fig. 10. Kinetics release profiles of MTX from different chitosan hydrogels (F1, F2, and F3) plotted according to first-order mechanism](image)
resistance to flow from the needle. This may be attributed to the high viscosity of this formula compared to β-GP and PL.

**Sol-Gel Transition Temperature Measurement**

All the prepared chitosan solutions undergo the sol to gel transition by changing the temperature (Table III). The mechanisms of these sol-to-gel transitions were believed to be shifting in equilibrium from unimer to micelle, micellar growth, or by micellar expansion accompanying an increase in aggregation number driven by hydrophobic or attractive forces [29, 44].

**In Vitro Drug Release**

In order to understand the ability of different chitosan systems to effectively deliver 5-FU and MTX in a sustained fashion, *in vitro* release studies were performed in phosphate buffer solution (pH 7.4) at 37°C under sink conditions. These conditions ensure that there are no changes in the previously measured physicochemical properties including viscosity and gelation point. The release profiles of 5-FU and MTX from different chitosan hydrogels are graphically illustrated in Figs. 5, 6, 7, and 8. Generally, the obtained results indicated that the release rate of MTX from different chitosan systems was higher than that of 5-FU (more than 50% of drug released within the first 2 days in all formulations). This order of drug release rates is intended to provide the synergistic effect of 5-FU and MTX combination, and it may be attributed to higher solubility of MTX with respect to 5-FU [4]. Regarding the effect of different chitosan hydrogel systems on the release profile of 5-FU, the results showed that the percentage of drug release was the highest from F1 hydrogel (95.3% within 2 weeks). This may be due to the lower viscosity of chitosan-β-GP hydrogel system compared to other systems (see results

---

**Table IV. Kinetic Data for Percentage of 5-FU and MTX Released from Different Hydrogel Systems**

| Kinetic models       | Different hydrogel systems |
|----------------------|----------------------------|
|                      | F1            | F2            | F3            | F4            |
|                      | 5-FU  | MTX  | 5-FU  | MTX  | 5-FU  | MTX  | 5-FU  | MTX  |
| Zero order           | r      | 0.997 | 0.783 | 0.973 | 0.798 | 0.983 | 0.844 | 0.973 | 0.962 |
|                      | Slope  | 6.642 | 4.30  | 4.683 | 2.156 | 3.586 | 8.628 | 3.302 | 9.857 |
| First order          | r      | 0.855 | 0.978 | 0.838 | 0.977 | 0.762 | 0.987 | 0.858 | 0.904 |
|                      | Slope  | 0.074 | 0.593 | 0.041 | 0.261 | 0.045 | 0.137 | 0.029 | 0.141 |
| Korsmeyer-Peppas     | r      | 0.987 | 0.964 | 0.964 | 0.952 | 0.906 | 0.979 | 0.940 | 0.970 |
|                      | Slope  | 0.128 | 0.474 | 0.131 | 0.267 | 0.062 | 0.560 | 0.607 | 0.689 |
| Higuchi diffusion    | r      | 0.948 | 0.947 | 0.861 | 0.960 | 0.914 | 0.962 | 0.858 | 0.997 |
|                      | Slope  | 2.400 | 7.093 | 1.849 | 4.868 | 1.740 | 3.170 | 1.561 | 3.170 |
| Best fitted model    | Zero   | First | Zero   | First | Zero   | First | Zero   | First |

---

**Fig. 11.** Kinetics release profile of MTX from chitosan hydrogel (F4) plotted according to Higuchi diffusion mechanism
of rheological characterization). The release of 5-FU from other chitosan hydrogel systems was arranged in the following descending order: F1 > F2 > F3 > F4.

On the other hand, the longest release of 5-FU was obtained from chitosan hydrogel system containing β-GP and 10% PL F127 combination (F4) which provided sustained release for more than 1 month in a good similarity with the chemotherapeutic cycle [47]. This finding can be explained by the higher affinity of the drug molecules to the hydrogel base if it is added during the formulation step which, consequently, hinders its release [48]. All experiments were carried out until complete drug release to exclude the possibility of drug engagement by the hydrogel base.

Kinetic Treatment of 5-FU and MTX Release Data

The release kinetic order of 5-FU and MTX from differently prepared chitosan hydrogel was determined simply using graphical representation methods [31]. The results indicate that the release of MTX from different chitosan hydrogels follows first-order kinetics in some formulations (F1, F2, and F3) and Higuchi diffusion model in F4. These results may be attributed to higher solubility of MTX which is used in its lyophilized forms. Thus, the released amounts directly affected by the initial amount in the formulæ. On the other hand, the release of 5-FU from different hydrogel formulations follows zero-order kinetics. These results suggested that chitosan hydrogel plays an important role in controlling release of the drug to the surrounding tissues (Figs. 9, 10, and 11; Table IV) [31].

CONCLUSION

Different chitosan hydrogel systems were successfully prepared. Chitosan hydrogel prepared using combination of β-GP and 10% PL F127 as cross-linking agents (F4) was found to have the longest duration of action (over 4 weeks) with good physicochemical properties, including pH, viscosity, syringeability, and injectability. Since the monthly injection of drug will be more convenient than frequent application; this system can be considered as a promising vehicle for quantitative release of anti-cancer drugs in a sustained manner.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Johnstone RW, Rueffli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108(2):153-64.
2. Ta HT, Dass CR, Dunstan DE. Injectable chitosan hydrogels for localised cancer therapy. J Control Release. 2008;126(3):205–16.
3. Longdey DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.
4. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science. 1979;205(4411):1135–7.
5. Bertino, J.R., E. Mini, and D.J. Fernandez. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. In Seminars in Oncology. 1983.
6. Langer R. New methods of drug delivery. Science. 1990;249(4976):1527–33.
7. Wolinsky JB, Colson YL, Grinstein MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159(1):14–26.
8. Xiong L, Luo Q, Wang Y, Li X, Shen Z, Zhu W. An injectable drug-loaded hydrogel based on a supramolecular polymeric prodrug. Chem Commun. 2015;51(78):14644–7.
9. Davis, M.E., Z. Chen, and D.M. Shin, Nanoparticle therapeutics: an emerging treatment modality for cancer, in Nanoscience And Technology: A Collection of Reviews from Nature Journals. 2010, World Scientific. p. 239–250.
10. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes a new frontier in cancer chemotherapy. Tumori J. 2003;89(3):237–49.
11. Shi Y, Li L. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv. 2005;2(6):1039–58.
12. Bhattachar N, Gunn J, Zhang M, Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010;62(1):83–99.
13. Cho J, Heuzy MC, Bégin A, Carreau PJ. Physical gelation of chitosan in the presence of β-glycerophosphate: the effect of temperature. Biomacromolecules. 2005;6(6):3267–75.
14. Klouda L, Mikos AG. Thermoresponsive hydrogels in biomedical applications. Eur J Pharm Biopharm. 2008;68(1):34–45.
15. Madhumathi K, Shalumon KT, Rani VVD, Tamura H, Furuike T, Selvamurugan N, et al. Wet chemical synthesis of chitosan hydrogel–hydroxyapatite composite membranes for tissue engineering applications. Int J Biol Macromol. 2009;45(1):12–5.
16. Liu J, Xiao Y, Allen C. Polymer–drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci. 2004;93(1):132–43.
17. Medina AR, de Córdova MF, Molina-Diaz A. Simultaneous determination of paracetamol, caffeine and acetylsalicylic acid by means of a FI ultraviolet pls multioptosensing device. J Pharm Biomed Anal. 2005;38(6):1485–94.
18. Roeges NP, Baas J. A guide to the complete interpretation of infrared spectra of organic structures. Chichester: Wiley; 1994. etc
19. Sturtevant JM. Biochemical applications of differential scanning calorimetry. Annu Rev Phys Chem. 1987;38(1):463–88.
20. Bruylants G, Wouters J, Michaux C. Differential scanning calorimetry in life science: thermodynamics, stability, molecular recognition and application in drug design. Curr Med Chem. 2005;12(17):2011–20.
21. Dinc E, Yucesoy C, Onur F. Simultaneous spectrophotometric determination of mefenamic acid and paracetamol in a pharmaceutical preparation using ratio spectra derivative spectrophotometry and chemometric methods. J Pharm Biomed Anal. 2002;28(6):1091–100.
22. Ruel-Gariépy E, Shive M, Bichara A, Berrada M, le Garrec D, Chentanez A, et al. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004;57(1):53–63.
23. Kim SW, Bae YH, Okano T. Hydrogels: swelling, drug loading, and release. Pharm Res. 1997;9(3):283–90.
24. Singh VK, Anis A, Banerjee I, Pramanik K, Bhattacharya MK, Pal K. Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosis. Mater Sci Eng C. 2014;44:151–8.

25. Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today. 2002;7(10):569–79.

26. Bowlt C. A simple capillary viscometer. Phys Educ. 1975;10(2):102–3.

27. Osman, K., Pharmaceutical studies on the availability of sildenafil citrate from certain topical delivery systems.

28. Ramstack, J.M., et al., Preparation of injectable suspensions having improved injectability. 2002, Google Patents

29. Jeong B, Kim SW, Bae YH. Thermosensitive sol–gel reversible hydrogels. Adv Drug Deliv Rev. 2012;64:154–62.

30. Khodaverdi E, Tafaghodi M, Ganji F, Abnoos K, Naghizadeh H. In vitro insulin release from thermosensitive chitosan hydrogel. AAPS PharmSciTech. 2012;13(2):460–6.

31. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–23.

32. Singhvi G, Singh M. In-vitro drug release characterization models. Int J Pharm Stud Res. 2011;2(1):77–84.

33. Higuchi WI. Diffusional models useful in biopharmaceutics: drug release rate processes. J Pharm Sci. 1967;56(3):315–24.

34. Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach: Springer Science & Business Media; 2003.

35. Selvaraj V, Alagar M. Analytical detection and biological assay of antileukemic drug 5-fluorouracil using gold nanoparticles as probe. Int J Pharm. 2007;337(1–2):275–81.

36. Raffique B, Khalid AM, Akhtar K, Jabbar A. Interaction of anticancer drug methotrexate with DNA analyzed by electrochemical and spectroscopic methods. Biosens Bioelectron. 2013;44:21–6.

37. Brugnerotto J, Lizardi J, Goycoolea FM, Argüelles-Monal W, Desbríeres J, Rinaudo M. An infrared investigation in relation with chitin and chitosan characterization. Polymert. 2001;42(8):3569–80.

38. Patro, S.K., et al. Drug-excipient compatibility studies using thermal methods

39. Tummala S, Kumar MS, Prakash A. Formulation and characterization of 5-fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharmaceutical J. 2015;23(3):308–14.

40. Sun Y, Cui F, Shi K, Wang J, Niu M, Ma R. The effect of chitosan molecular weight on the characteristics of spray-dried methotrexate-loaded chitosan microspheres for nasal administration. Drug Dev Ind Pharm. 2009;35(3):379–86.

41. Kittur F, et al. Characterization of chitin, chitosan and their carboxymethyl derivatives by differential scanning calorimetry. Carbohydr Polym. 2002;49(2):185–93.

42. DeLean A, Munson P, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol Endocrinol Metab. 1978;235(2):E97.

43. Eslahi N, Abdorahim M, Simchi A. Smart polymeric hydrogels for cartilage tissue engineering: a review on the chemistry and biological functions. Biomacromolecules. 2016;17(11):3441–63.

44. Liu D-M, Troczynski T, Tseng WJ. Water-based sol–gel synthesis of hydroxyapatite: process development. Biomaterials. 2001;22(13):1721–30.

45. Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev. 2008;37(8):1473–81.

46. Ciuruzzo F, Selmin F, Mighetti P, Adami M, Bertoni E, Lauria S, et al. Injectability evaluation: an open issue. AAPS PharmSciTech. 2011;12(2):604–9.

47. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281–8.

48. Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm. 2000;197(1–2):1–11.